Compare NUVL & SKM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | SKM |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.9B |
| IPO Year | 2021 | 1996 |
| Metric | NUVL | SKM |
|---|---|---|
| Price | $105.83 | $23.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 1 |
| Target Price | ★ $135.00 | N/A |
| AVG Volume (30 Days) | 548.0K | ★ 734.1K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.89 |
| Revenue | N/A | ★ $12,327,044,068.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.05 |
| P/E Ratio | ★ N/A | $22.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $19.66 |
| 52 Week High | $112.88 | $23.80 |
| Indicator | NUVL | SKM |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 82.18 |
| Support Level | $97.43 | $20.19 |
| Resistance Level | $108.65 | $21.13 |
| Average True Range (ATR) | 4.95 | 0.27 |
| MACD | 0.48 | 0.21 |
| Stochastic Oscillator | 82.96 | 95.86 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.